Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOXIL-2: Optimizing rIL-2 Uptake in HIV
NCT00147355Phase 3Terminated
- Sponsor
- The Kirby Institute
- Start
- Nov 2005
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ondansetron, metoclopramide and codeine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by The Kirby Institute. Primary endpoint: Percentage of planned rIL-2 taken during the first rIL-2 dosing cycle at 6 months. Started Nov 2005; status: terminated.
02
Drugs
ondansetronmetoclopramidecodeine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00147355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147355.